Evidence map›Paper›PMID 36221029›Full record

ArticleScientific reports2022

Local monitoring of SARS-CoV-2 variants in two large California counties in 2021.

Noah Kojima, Eugenia Khorosheva, Lauren Lopez, Mikhail Hanewich-Hollatz, J Cesar Ignacio-Espinoza, Matthew Brobeck, Janet Chen, Matthew Geluz, Victoria Hess, Sophia Quasem and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Noah KojimaDepartment of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA. nkojima@ucla.edu.
Eugenia KhoroshevaCurative Inc., San Dimas, CA, USA.
Lauren LopezCurative Inc., San Dimas, CA, USA.
Mikhail Hanewich-HollatzCurative Inc., San Dimas, CA, USA.
J Cesar Ignacio-EspinozaCurative Inc., San Dimas, CA, USA.
Matthew BrobeckCurative Inc., San Dimas, CA, USA.
Janet ChenCurative Inc., San Dimas, CA, USA.
Matthew GeluzCurative Inc., San Dimas, CA, USA.
Victoria HessCurative Inc., San Dimas, CA, USA.
Sophia QuasemCurative Inc., San Dimas, CA, USA.
Nabjot SandhuCurative Inc., San Dimas, CA, USA.
Elias SalfatiCurative Inc., San Dimas, CA, USA.
Maria ShacreawCurative Inc., San Dimas, CA, USA.
George WayCurative Inc., San Dimas, CA, USA.
Zhiyi XieCurative Inc., San Dimas, CA, USA.
Vladimir SlepnevCurative Inc., San Dimas, CA, USA.
Jeffrey D KlausnerDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA.
University of California, Los Angeles · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to persist due to mutations resulting in newer, more infectious variants of concern. We aimed to leverage an ongoing private SARS-CoV-2 testing laboratory's infrastructure to monitor SARS-CoV-2 variants in two large California counties. Study enrollment was offered to adults aged 18 years or older in Los Angeles County and Riverside County who recently tested positive for SARS-CoV-2 with a polymerase chain reaction (PCR) assay. A cycle threshold value less than or equal to 30 cycles was considered a positive test for sequencing purposes. Within 5 days of study enrollment, clinician-monitored, self-collected oral fluid and anterior nares swab specimens were obtained from participants. Specimens were transported and stored at 8 °C or cooler. Samples underwent ribonucleic acid extraction, library preparation, and sequencing. SARS-CoV-2 lineages were identified using sequencing data. Participant and genomic data were analyzed using statistical tools and visualized with toolkits. The study was approved by Advarra Institutional Review Board (Pro00053729). From May 27, 2021 to September 9, 2021, 503 individuals were enrolled and underwent specimen collection. Of the 503 participants, 238 (47.3%) participants were women, 329 (63.6%) participants were vaccinated, and 221 (43.9%) participants were of Hispanic or Spanish origin. Of the cohort, 496 (98.6%) participants had symptoms at the time of collection. Among the 503 samples, 443 (88.1%) nasal specimens and 353 (70.2%) oral specimens yielded positive sequencing results. Over our study period, the prevalence of the Alpha variant of SARS-CoV-2 decreased (initially 23.1% [95% confidence interval (95% CI): 0-0.49%] to 0% [95% CI 0.0-0.0%]) as the prevalence of the Delta variant of SARS-CoV-2 increased (initially 33.3% [95% CI 0.0-100.0%] to 100.0% [95% CI 100.0-100.0%]). A strain that carried mutations of both Delta and Mu was identified. We found that outpatient SARS-CoV-2 variant surveillance could be conducted in a timely and accurate manner. The prevalence of different variants changed over time. A higher proportion of nasal specimens yielded results versus oral specimens. Timely and regional outpatient SARS-CoV-2 variant surveillance could be used for public health efforts to identify changes in SARS-CoV-2 strain epidemiology.

Indexed as

COVID-19SARS-CoV-2AdultCOVID-19 TestingFemaleHumansMaleRNARNA

Identifiers

PMID36221029
PMCPMC9553084
OpenAlexW4304205574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.